XML 29 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended 185 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Dec. 31, 2011
Revenues:        
Collaboration and research and development revenue   $ 100   $ 3,100
Product Revenue 699 574 910 3,021
Grant revenue   12 1 3,648
Total revenues 699 686 911 9,769
Operating expenses:        
Cost of goods sold 360 418 545 1,752
Research and development 9,206 6,414 9,766 185,799
Selling, general and administrative 7,521 10,120 8,538 89,487
Goodwill and intangibles impairment       7,934
Other restructuring costs     366 2,634
Total operating expenses 17,087 16,952 19,215 287,606
Operating loss (16,388) (16,266) (18,304) (277,837)
Other income (expense):        
Costs associated with aborted 2004 IPO       (3,550)
Payment under guarantee     (1,652) (1,652)
Change in valuation of derivative (20)     (328)
Change in valuation of warrants liability 629 (338) (299) 6,699
Warrant re-pricing     (44) (44)
Foreign exchange losses (74) (68) (144) (4,329)
Interest income 45 37 102 13,725
Interest expense   (43) (177) (4,677)
Total other (expense) income, net 580 (412) (2,214) 5,844
Loss before taxes (15,808) (16,678) (20,518) (271,993)
Income tax benefit 565 657 948 18,444
Net loss (15,243) (16,021) (19,570) (253,549)
Dividend on preferred ordinary shares       (38,123)
Deemed dividend on convertible exchangeable preferred shares   (3,515)   (3,515)
Dividend on convertible exchangeable preferred shares (728) (167) (1,228) (3,657)
Net loss applicable to common shareholders $ (15,971) $ (19,703) $ (20,798) $ (298,844)
Net loss per share - basic and diluted (in dollars per share) $ (0.32) $ (0.52) $ (0.94)  
Weighted average common shares outstanding (in shares) 50,301,144 37,844,695 22,196,840